{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:56Z","timestamp":1761895076767},"reference-count":37,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is not clear if absence of BCR-ABL transcripts\u2014complete molecular response (CMR)\u2014is synonymous with, or required for, cure of chronic myeloid leukemia (CML). Some patients achieve CMR with imatinib (IM), but most relapse shortly after treatment discontinuation. Furthermore, most patients in long-term remission (LTR) post\u2013stem cell transplantation (SCT) are considered functionally cured, although some remain occasionally positive for low-level BCR-ABL mRNA. Interpretation of the latter is complicated because it has been observed in healthy subjects. We designed a patient-specific, highly sensitive, DNA quantitative polymerase chain reaction to test follow-up samples for the original leukemic clone, identified by its unique genomic BCR-ABL fusion (gBCR-ABL). In 5 IM-treated patients in CMR, gBCR-ABL was detected in transcript-negative samples; 4 patients became gBCR-ABL-negative with continuing IM therapy. In contrast, of 9 patients in LTR (13-27 years) post-SCT, gBCR-ABL was detected in only 1, despite occasional transcript-positive samples in 8 of them. In conclusion, in IM-treated patients, absence of transcripts should not be interpreted as absence of the leukemic clone, although continuing IM after achievement of CMR may lead to further reduction of residual disease. Post-SCT, we found little evidence that the transcripts occasionally detected originate from the leukemic clone.<\/jats:p>","DOI":"10.1182\/blood-2009-11-255109","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T22:44:28Z","timestamp":1273704268000},"page":"1329-1335","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib"],"prefix":"10.1182","volume":"116","author":[{"given":"Manuel","family":"Sobrinho-Sim\u00f5es","sequence":"first","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom;"},{"name":"Service of Clinical Hematology, Hospital S Jo\u00e3o and Medical Faculty of the University of Porto, Porto, Portugal;"}]},{"given":"Vicki","family":"Wilczek","sequence":"additional","affiliation":[{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; and"}]},{"given":"Joannah","family":"Score","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, and Human Genetics Division, University of Southampton School of Medicine, Southampton, United Kingdom"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, and Human Genetics Division, University of Southampton School of Medicine, Southampton, United Kingdom"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom;"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom;"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; and"}]}],"member":"234","reference":[{"issue":"4944","key":"2019111802061357400_B1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"10","key":"2019111802061357400_B2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111802061357400_B3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"35","key":"2019111802061357400_B4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111802061357400_B5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111802061357400_B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111802061357400_B7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000046635","article-title":"Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.","volume":"107","author":"Kaeda","year":"2002","journal-title":"Acta Haematol"},{"issue":"12","key":"2019111802061357400_B8","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"2019111802061357400_B9","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362.421k17_3362_3367","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111802061357400_B10","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"issue":"4","key":"2019111802061357400_B11","first-page":"609","article-title":"Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.","volume":"14","author":"van Rhee","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111802061357400_B12","first-page":"83","article-title":"Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.","volume":"4","author":"Pignon","year":"1990","journal-title":"Leukemia"},{"issue":"3","key":"2019111802061357400_B13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","article-title":"Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.","volume":"115","author":"Mughal","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111802061357400_B14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V98.6.1701","article-title":"The significance of bcr-abl molecular detection in chronic myeloid leukemia patients \u201dlate,\u201c 18 months or more after transplantation.","volume":"98","author":"Radich","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2019111802061357400_B15","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111802061357400_B16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1701729","article-title":"Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation.","volume":"23","author":"Yong","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2019111802061357400_B17","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111802061357400_B18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111802061357400_B19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.","volume":"84","author":"Foroni","year":"2009","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111802061357400_B20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"issue":"1","key":"2019111802061357400_B21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"11","key":"2019111802061357400_B22","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood.V84.11.3984.bloodjournal84113984","article-title":"Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.","volume":"84","author":"Melo","year":"1994","journal-title":"Blood"},{"key":"2019111802061357400_B23","doi-asserted-by":"crossref","article-title":"Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.","author":"Score","DOI":"10.1038\/leu.2010.174"},{"issue":"23","key":"2019111802061357400_B24","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.1093\/nar\/16.23.10953","article-title":"Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells.","volume":"16","author":"Jeffreys","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2019111802061357400_B25","first-page":"1217","article-title":"Reverse transcription\/polymerase chain reaction (RT\/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"2019111802061357400_B26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.leu.2404082","article-title":"Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.","volume":"20","author":"Burmeister","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111802061357400_B27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.","volume":"21","author":"van Der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"2019111802061357400_B28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.","volume":"17","author":"van Der Velden","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111802061357400_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111802061357400_B30","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"issue":"24","key":"2019111802061357400_B31","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","article-title":"Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia.","volume":"5","author":"Barnes","year":"2006","journal-title":"Cell Cycle"},{"issue":"10","key":"2019111802061357400_B32","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111802061357400_B33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"2019111802061357400_B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000089476","article-title":"Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.","volume":"115","author":"Verbeek","year":"2006","journal-title":"Acta Haematol"},{"issue":"5","key":"2019111802061357400_B35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2353\/jmoldx.2009.080150","article-title":"Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.","volume":"11","author":"Mattarucchi","year":"2009","journal-title":"J Mol Diagn"},{"issue":"8","key":"2019111802061357400_B36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia.","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111802061357400_B37","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V87.6.2588.bloodjournal8762588","article-title":"Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.","volume":"87","author":"Zhang","year":"1996","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/8\/1329\/1333843\/zh803410001329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/8\/1329\/1333843\/zh803410001329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T02:06:32Z","timestamp":1574042792000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/8\/1329\/27858\/In-search-of-the-original-leukemic-clone-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,26]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-11-255109","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,26]]}}}